Genomic Vision

Genomic Vision ROE

The Return on Equity (ROE) of Genomic Vision (GV.PA) as of Oct 22, 2026 is 526.76 %. In the previous year, Return on Equity (ROE) was -162.80 % — a change of -423.56% (higher).

ROE

526.76 %

YoY

-423.56%

Last updated:

In 2022, Genomic Vision's return on equity (ROE) was 526.76 %, a -423.56% increase from the -162.80 % ROE in the previous year.

The Genomic Vision ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
-23.60 EUR
Jan 1, 2016
-85.83 EUR
Jan 1, 2017
-241.44 EUR
Jan 1, 2018
-165.54 EUR
Jan 1, 2019
-142.80 EUR
Jan 1, 2020
-165.77 EUR
Jan 1, 2021
-162.80 EUR
Jan 1, 2022
526.76 EUR
The Genomic Vision ROE history
YEARROEYoY
526.76 %-423.56%
-162.80 %-1.79%
-165.77 %+16.09%
-142.80 %-13.74%
-165.54 %-31.44%
-241.44 %+181.30%
-85.83 %+263.66%
-23.60 %+148.50%
-9.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

ROE Details

Decoding Genomic Vision's Return on Equity (ROE)

Genomic Vision's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Genomic Vision's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Genomic Vision's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Genomic Vision’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Genomic Vision stock

Return on Equity (ROE) of Genomic Vision is 526.76 % in 2022.

Return on Equity (ROE) of Genomic Vision changed from -162.80 % to 526.76 %, representing a -423.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Genomic Vision with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Genomic Vision

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Genomic Vision